Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor

Journal of Clinical Investigation

Volumn 99, Issue 12, 1997, Pages 2837-2841

  Dibbern Jr , Donald A ^a   Glazner, Gordon W ^a   Gozes, Illana ^b   Brenneman, Douglas E ^a   Hill, Joanna M ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Activity dependent neurotrophic factor; Embryo; Growth retardation; Human immunodeficiency virus gp120; Vasoactive intestinal peptide

Indexed keywords

DNA; GLYCOPROTEIN GP 120; NEUROTROPHIC FACTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; EMBRYO GROWTH; GROWTH INHIBITION; GROWTH RETARDATION; HUMAN IMMUNODEFICIENCY VIRUS; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SOMITE;

EID: 1842338686     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119476     Document Type: Article

References (69)

1. McCormick, M.C. 1985. The contribution of low birth weight to infant mortality and childhood morbidity. N. Engl. J. Med. 312:82-89.
2. Hira, S.K., J. Kamanga, G.J. Bhat, C. Mwale, G. Tembo, N. Luo, and P.L. Perine. 1989. Perinatal transmission of HIV-I in Zambia. Br. Med. J. 299:1250-1252.
3. Lallemant, M., S. Lallemant-Le-Coeur, D. Cheynier, S. Nzingoula, G. Jourdain, M. Sinet, M.-C. Dazza, S. Blanche, C. Griscelli, and B. Larouzé. 1989. Mother-child transmission of HIV-1 and infant survival in Brazzaville, Congo. AIDS (Lond.). 3:643-646.
4. Kumar, R.M., S.A. Uduman, and A.K. Khurranna. 1995. Impact of maternal HIV infection on perinatal outcome. Int. J. Gynaecol. Obstet. 49:137-143.
5. Braddick, M.R., J.K. Kreiss, J.E. Embree, P. Datta, J.O. Ndinya-Achola, H. Pamha, G. Maitha, P.L. Roberts, T.C. Quinn, K.K Holmes, et al. 1990. Impact of maternal HIV infection on obstetrical and early neonatal outcome. AIDS (Lond.). 4:1001-1005.
6. Bulterys, M., A. Chao, S. Munyeman. J.B. Kurawige, M.S. Nawrocki, P. Habimana, M. Kageruka, S. Mukantabana, E. Mbarutso, A. Dushimimana, and A. Saah. 1994. Maternal human immunodeficiency virus 1 infection and intrauterine growth: a prospective cohort study in Butare, Rwanda. Pediatr. Infect. Dis. J. 13:94-100.
7. Lepage, P., P. Msellati, P. Van de Perre, D.-G. Hitimana, and F. Dabis. 1992. Characteristics of newborns and HIV-1 infection in Rwanda. AIDS (Lond.). 6:882-883.
8. Ades, A.E., M.L. Newell, and C.S. Peckham. 1991. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet. 337:253-260.
9. Ryder, R.W., W. Nsa, S.E. Hassig, F. Behets, M. Rayfield, B. Ekungola, A.M. Nelson, U. Mulenda, H. Francis, K. Mwandagalirwa, et al. 1989. Perinatal transmission of the human immunodeficiency virus type 1 to infants of seropositive women in Zaire. N. Engl. J. Med. 320:1637-1642.
10. Taha, T.E., G.A. Dallabetta, J.K. Canner, J.D. Chiphangwi, G. Liomba, D.R. Hoover, and P.G. Miotti. 1995. The effect of human immunodeficiency virus infection on birthweight, and infant and child mortality in urban Malawi. Int. J. Epidemiol. 24:1022-1029.
11. Halsey, N.A., R. Boulos, E. Holt, A. Ruff, J.-R. Brutus, P. Kissinger, T.C. Quinn, J.S. Coberly, M. Adrien, and C. Boulos. 1990. Transmission of HIV-1 infections from mothers to infants in Haiti. Impact on childhood mortality and malnutrition. JAMA (J. Med. Am. Assoc.). 264:2088-2092.
12. Mok,J.Y.Q., R.A. Hague, P.L Yap, F.D. Hargreaves, J.M. Inglis, J.M. Whitelaw, C.M. Steele, P.B. Eden, S. Rebus, J.F. Peutherere, et al. 1989. Vertical transmission of HIV: a prospective study. Arch. Dis. Child. 64:1140-1145.
13. Gabiano, C., P. Tovo, M. deMartino, L. Galli, C. Giaquinto, A. Loy, M.C. Schoeller, M. Giovannini, G. Ferranti, L. Rancilio, et al. 1992. Mother-to-child transmission of human immunodeficiency virus type 1: risk of infection and correlates of transmission. Pediatrics. 90:369-374.
14. McKinney, R.E., Jr., J.W.R. Robertson, and the Duke Pediatric AIDS Clinical Trials Unit. 1993. Effect of human immunodeficiency virus infection on the growth of young children. J. Pediatr. 123:579-582.
15. Cortey, A., J.G. Jarvik, R.E. Lenkinski, R.I. Grossman, I. Frank, and M. Delivoria-Papadopoulos. 1994. Proton MR spectroscopy of brain abnormalities in neonates born to HIV-positive mothers. AJNR. 15:1853-1859.
16. Brenneman, D.E., G.L. Westbrook, S.P. Fitzgerald, D.L. Ennist, K.L. Elkins, M.R. Ruff, and C.B. Pert. 1988. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature (Lond.). 335:639-642.
17. Hill, J.M., R.F. Mervis, R. Avidor, T.W. Moody, and D.E. Brenneman. 1993. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res. 603:222-233.
18. Dreyer, E.B., P.K. Kaiser, J.T. Offermann, and S.A. Lipton. 1990. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science (Wash. DC). 248:364-367.
19. Lipton, S.A., N.J. Sucher, P.K. Kaiser, and E.B. Dreyer. 1991. Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. Neuron. 7:111-118.
20. Glowa, J.R., L.V. Panlilio, D.E. Brenneman, I. Gozes, M. Fridkin, and J.M. Hill. 1992. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res. 570:49-53.
21. Toggas, S.M., E. Masliah, E.M. Rockenstein, G.F. Rail, C.R. Abraham, and L. Mucke. 1994. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature (Lond.). 367:188-193.
22. Mittler, R.S., and M.K. Hoffmann. 1989. Synergism between HIV gp120 and ep120-specific antibody in blocking human T cell activation. Science (Wash. DC). 245:1380-1382.
23. Mann, D.L., F. Lasane, M. Popovic, L.O. Arthur, W.G. Robey, W.A. Blattner, and M.J. Newman. 1987. HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis. J. Immunol. 138:2640-2644.
24. + T lymphocytes by inhibiting interleukin 2 mRNA, Proc. Natl. Acad. Sci. USA. 87:2379-2383.
25. Chirmule, N., V.S. Kalyanaraman, N. Oyaizu, H.B. Slade, and S. Pahwa. 1990. Inhibition of functional properties of tetanus antigen-specific T-cell clones by envelope glycoprotein gp120 of human immunodeficiency virus. Blood. 75:152-159.
26. Weinhold, K.J., H.K. Lyerly, S.D. Stanley, A.A. Austin, T.J. Matthews, and D.P. Bolognesi. 1989. HIV-1 gp120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J. Immunol. 142:3091-3097.
27. Sundar, S.K., M.A. Cierpial, L.S. Kamaraju, S. Long, S. Hsieh, C. Lorenz, M. Aaron, J.C. Ritchie, and J.M. Weiss. 1991. Human immunodeficiency virus glycoprotein (gp120) infused into rat brain induces interleukin 1 to elevate pituitary-adrenal activity and decrease peripheral cellular immune responses. Proc. Natl. Acad. Sci. USA. 88:11246-11250.
28. Arock, M., A. Dedenon, L. Le Goff, A. Michel, G. Missenard, P. Debre, and J.J. Guillosson. 1994. Specific ligation of the HIV-1 viral envelope protein gp120 on human CD34+ bone marrow-derived progenitors. Cell. Mol. Biol. 40: 319-323.
29. Wahl, L.M., M.L. Corcoran, S.W. Pyle, L.O. Arthur, A. Harel-Bellan, and W.L. Farrar. 1989. Human immunodeficiency virus glycoprotein (gp120) induction of monocyte arachidonic acid metabolites and interleukin 1. Proc. Natl. Acad. Sci. USA. 86:621-625.
30. Wahl, S.M., J.B. Allen, S. Gartner, J.M. Orenstein, M. Popovic, D.E. Chenoweth, L.O. Arthur, W.L. Farrar, and L.M. Wahl. 1989. HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J. Immunol. 142:3553-3559.
31. Brenneman, D.E., and L.E. Eiden. 1986. Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc. Natl. Acad. Sci. USA. 83:1159-1162.
32. Brenneman, D.E., E.A. Neale, G.A. Foster, S. d'Autrement, and G.L. Westbrook. 1987. Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide. J. Cell Biol. 104:1603-1610.
33. Gressens, P., J.M. Hill, I. Gozes, M. Fridkin, and D.E. Brenneman. 1993. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature (Lond.). 362:155-158.
34. Gressens, P., J.M. Hill, B. Paindaveine, I. Gozes, M. Fridkin, and D.E. Brenneman. 1994. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J. Clin. Invest. 94:2020-2027.
35. Hill, J.M., S.K. McCune, R.J. Alvero, G.W. Glazner, K.A. Henins, S.F. Stanziale, J.R. Keimowitz, and D.E. Brenneman. 1996. Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent. J. Clin. Invest. 97:202-208.
36. Brenneman, D.E., J.M. Hill, G.W. Glazner, I. Gozes, and T.W. Phillips. 1995. Interleukin-1 alpha and vasoactive intestinal peptide: engimatic regulation of neuronal survival. Int. J. Dev. Neurosci. 13:187-200.
37. Festoff, B.E., P.G. Nelson, and D.E. Brenneman. 1996. Prevention of activity-dependent neuronal death: vasoactive intestinal polypeptide stimulates astrocytes to secrete the thrombin-inhibiting, neurotrophic serpin, protease nexin 1. J. Neurobiol. 30:255-266.
38. Brenneman, D.E., and I. Gozes. 1996. A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97:2299-2307.
39. Glazner, G.W., J.Y. Wu, P. Gressens, I. Gozes, D.E. Brenneman, and J.M. Hill. 1995. Vasoactive intestinal peptide stimulation of embryonic growth in cultured E9 mice is partially mediated through activity-dependent neurotrophic factor. Soc. Neurosci. Abstr. 21:1545.
40. Kaufman, M.H. 1992. The Atlas of Mouse Development. Academic Press Inc., New York. 512 pp.
41. Brown, N.A., and S. Fabro. 1981. Quantitation of rat embryonic development in vitro: a morphological scoring system. Terotology. 24:65-78.
42. New, D.A.T. 1971. Methods for the culture of postimplantation embryos of rodents, in Methods in Mammalian Embryology. J.C. Daniel, Jr., editor. W.H. Freeman & Co., San Francisco, CA. 305-319.
43. Van Maele-Fabry, G., J.P. Debras, I. Francois, M. Boucau, and J.J. Picard. 1988. Sera as culture media for 8.5 days whole mouse embryos. Archs. Biol. 99:431-453.
44. Burton, K. 1956. Study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J. 62:315-323.
45. Munro, H.N. 1968. The determination of nucleic acids. Methods in Biochemical Analysis. 14:113-176.
46. Bradford, M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
47. Oh, S.-K., W.W. Cruikshank, J. Raina, G.C. Blanchard, W.H. Adler, J. Walker, and H. Kornfeld. 1992. Identification of HIV-1 envelope glycoprotein in the serum of AIDS and ARC patients. J. Acquired Immune Defic. Syndr. 5: 251-256.
48. Buzy, J., D.E. Brenneman, C.B. Pert, A. Martin, A. Salazar, and M.R. Ruff. 1992. Potent gp120-like neurotoxicity in the cerebrospinal fluid of HIV-infected individuals is blocked by peptide T. Brain Res. 598:10-18.
49. Wu, J.Y., T.W. Moody, D.E. Brenneman, and J.M. Hill. 1994. Fetal brain accumulates gp120 systemically administered to pregnant mice. Soc. Neurosci. Abstr. 20:1258.
50. Maury, W., B.J. Potts, and A.B. Rabson. 1989. HIV-1 infection of firsttrimester and term human placental tissue: a possible mode of maternal-fetal transmission. J. Infect. Dis. 160:583-588.
51. Sprecher, S., F. Soumenkoss, F. Puissant, and M. Degueldre. 1986. Vertical transmission of HIV in 15-week fetus. Lancet. ii:288-289.
52. Franks, R.A., P.E. Ray, C.C. Babbott, J.L. Bryand, A.L. Notkins, T.J. Santoro, and P.E. Klotman. 1995. Maternal-fetal interactions affect growth of human immunodeficiency virus type 1 transgenic mice. Pediatr. Res. 37:56-63.
53. Pulliam, L., D. West, N. Haigwood, and R.A. Swanson. 1993. HIV-1 envelope gp120 alters astrocytes in human brain cultures. AIDS Res. Hum. Retro-viruses. 9:439-444.
54. Yeung, M.C., L. Pulliam, and A.S. Lau. 1995. The HIV envelope protein gp120 is toxic to human brain-cell cultures through the induction of interleukin-6 and tumor necrosis factor-alpha. AIDS (Lond.). 9:137-143.
55. Koka, P., K. He, J.A. Zack, S. Kitchen, W. Peacock, I. Fried, T. Tran, S.S. Yashar, and J.E. Merrill. 1995. Human immunodeficiency virus 1 envelope proteins induce interleukin 1, tumor necrosis factor alpha, and nitric oxide in glial cultures derived from fetal, neonatal, and adult human brain. J. Exp. Med. 182:941-951.
56. Mollace, V., M. Colasanti, T. Persichini, G. Bagetta, G.M. Lauro, and G. Nistico. 1993. HIV gp120 glycoprotein stimulates the inducible isoform of NO synthase in human cultured astrocytoma cells. Biochem. Biophys. Res. Commun. 194:439-445.
57. Tabatabaie, T., C. Stewart, Q. Fye, Y. Katoako, and R.A. Floyd. 1996. In vivo trapping of nitric oxide in the brain of neonatal rats treated with the HIV-1 envelope protein gp120: protective effects of alpha-phenyl-tert-butylnitrone. Biochem. Biophys. Res. Commun. 221:386-390.
58. Dawson, V.L., T.M. Dawson, G.R. Uhl, and S.H. Snyder. 1993. Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc. Natl. Acad. Sci. USA. 90:3256-3259.
59. Lipton, S.A. 1992. Requirement for macrophages in neuronal injury induced by HIV envelope protein gp120. Neuroreport. 3:913-915.
60. Giulian, D., E. Wendt, K. Vaca, and C.A. Noonan. 1993. The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes. Proc. Natl. Acad. Sci. USA. 90:2769-2773.
61. Lipton, S.A. 1994. HIV-related neuronal injury. Potential therapeutic intervention with calcium channel antagonists and NMDA antagonists. Mol. Neurobiol. 8:181-196.
62. Dawson, T.M., V.L. Dawson, and S.H. Snyder. 1994. Molecular mechanisms of nitric oxide actions in the brain. Ann. N.Y. Acad. Sci. 738:76-85.
63. Said, S.I., H.I. Berisha, and H. Pakbaz. 1996. Excitotoxicity in the lung: N-methyl-D-aspartate-induced, nitricoxide-dependent, pulmonary edema is attenuated by vasoactiveintestinal peptide and by inhibitors of poly(ADP-ribose)polymerase. Proc. Natl. Acad. Sci. USA. 93:4688-4692.
64. Heyes, M.P., B.J. Brew, A. Martin, R.W. Price, A.M. Salazar, J.J. Sidtis, J.A. Yergey, M.M. Mouradian, A.E. Sadler, J. Keilp, et al. 1991. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann. Neurol. 29:202-209.
65. Sci. S., K. Saito, S.K. Stewart, J.S. Crowley, P. Brouwers, D.E. Kleiner, D.A. Katz, P.A. Pizzo, and M.P. Heyes. 1995. Increased human immunodeficiency virus (HIV) type 1 DNA content and quinolinic acid concentration in brain tissues from patients with HIV encephalopathy. J. Infect. Dis. 172:638-647.
66. Gendelman, H.E., S.A. Lipton, M. Tardieu, M.I. Bukrinsky, and H.S. Nottet. 1994. The neuropathogenesis of HIV-1 infection. J. Leukocyte Biol. 56: 389-398.
67. Giulian, D., K. Vaca, and C.A. Noonan. 1990. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science (Wash. DC). 250: 1593-1596.
68. Hill, J.M., D.V. Agoston, P. Gressens, and S.K. McCune. 1994. Distribution of VIP mRNA and two distinct VIP binding sites in the developing rat brain: relation to ontogenic events. J. Comp. Neurol. 342:186-205.
69. Hill, J.M., P. Gressens, G.W. Glazner, and D.E. Brenneman. 1996. Floor plate neuroepithelium has binding sites for growth regulator, vasoactive intestinal peptide. Soc. Neurosci. Abstr. 22:1478.